Home>>Signaling Pathways>> Others>>Progabide (SL 76002)

Progabide (SL 76002)

Catalog No.GC33521

Progabide (SL 76002) is a gamma-aminobutyric acid receptor (GABA) agonist.

Products are for research use only. Not for human use. We do not sell to patients.

Progabide (SL 76002) Chemical Structure

Cas No.: 62666-20-0

Size Price Stock Qty
5mg
$50.00
In stock
10mg
$81.00
In stock
25mg
$166.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Progabide is a gamma-aminobutyric acid receptor (GABA) agonist.

Progabide is a gamma-aminobutyric acid receptor (GABA) agonist. Doses of 50, 100 and 200 mg/kg Progabide given IP to male Wistar rats increase the plasma corticosterone levels by 244, 365 and 476% respectively (t=6.44 to12.55, p<0.01). 10 mg/kg of Progabide fails to change the concentration of corticosterone in plasma (t=0.76, N.S.). The increased plasma corticosterone level induced by administration of 200 mg/kg Progabide is evident 30 (t=2.625, p<0.05), 60 (t=13.13, p<0.001) and 120 min (t=4.07, p<0.01) after drug injection, but returns to the control value 240 min after drug injection (t=0.86, N.S.). The greatest corticosterone rise (compare with the corresponding control) is reached 60 min following the administration of Progabide[1].

[1]. Manev H, et al. Progabide, a GABA mimetic drug, stimulates the secretion of plasma corticosterone in rats. Pharmacol Biochem Behav. 1987 Dec;28(4):443-6.

Reviews

Review for Progabide (SL 76002)

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Progabide (SL 76002)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.